US Pharma MarketingA June flourish lifts biotech megaround tally in first half of 2026
Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally.
That's more than the same period of 2025 ...
Source: Endpoints News